OpiCalc

Favorites Specialties Drugs Guidelines Most Used

All Specialties

Favorites Specialties Drugs Guidelines Most Used

Faves Specs Drugs Guides Top

APGAR Score Assisted Delivery (FIGO)BPP (Manning Score)Bishop Score CARPREG II Cardiac Risk Cervical Cancer Staging Contraceptive Pearl Index Doppler Matrix (UA/MCA)EFW (Hadlock)Endometrial Staging Endometrial Thickness FGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey Score Fetal Anemia (MCA PSV)GDM Diagnostic Criteria GPA History Indicator Gail Model Breast Risk Gestational Dating (LMP)HIV PMTCT Protocol IOTA Simple Rules IVF Due Date & AMH Iron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS Classification Ovarian Cancer Staging PAS Hemorrhage Risk PPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS Criteria Syphilis Management TORCH Framework VBAC Success Probability Vulvar Cancer Staging Weight Gain (IOM)mWHO Cardiac Risk

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required

Ready for the Bedside

Resources

About Us Editorial Policy Medical Disclaimer Privacy Policy Terms of Use Cookie Policy

Support

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

In Recent Clinical News

Scanning Medical Journals

No new significant updates or guidelines matching this topic were found today. We will check again soon.

Gail Model Breast Risk

Gail Model Breast Risk

Breast Cancer Risk Assessment Tool (BCRAT)

Current Age

Age at Menarche

Age at First Live Birth

First-Degree Relatives w/ Breast Ca

Number of Prior Breast Biopsies

Note: The Gail Model is most accurate for women over 35 without a personal history of LCIS or DCIS. A 5-year risk ≥ 1.67% is considered "high risk" and may justify chemoprevention.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Primary Clinical Uses

Estimating the 5-year and lifetime risk of developing invasive breast cancer in women aged 35 years and older.

Determining eligibility for prophylactic breast cancer risk-reducing medications (Tamoxifen/Raloxifene).

Triaging patients for enhanced screening protocols (e.g., adjunctive Breast MRI).

Exclusion Criteria

This tool is useless and invalid for patients with known BRCA1/BRCA2 genetic mutations, patients with a history of Lobular/Ductal Carcinoma In Situ (LCIS/DCIS), or those who have received prior medical radiation to the chest.

Last Comprehensive Review: 2026